A PK/PD model for the evaluation of clinical rifaximin dosage for the treatment of dairy cow mastitis induced by Escherichia coli
暂无分享,去创建一个
Xiaojie Chen | Xiubo Li | Jingju Zhang | Honglei Wang | Chun-Xu Liu | Yufeng Wang | Chen Chen | Yiming Liu | Mingyue Han
[1] Yuan Liu,et al. PK/PD integration and pharmacodynamic cutoff of cefquinome against cow mastitis due to Escherichia coli. , 2021, Journal of veterinary pharmacology and therapeutics.
[2] Xiaojie Chen,et al. PK/PD Modeling to Assess Rifaximin Clinical Dosage in a Mouse Model of Staphylococcus aureus-Induced Mastitis , 2021, Frontiers in Veterinary Science.
[3] A. Bandoni,et al. Melaleuca armillaris Essential Oil in Combination With Rifaximin Against Staphylococcus aureus Isolated of Dairy Cows , 2020, Frontiers in Veterinary Science.
[4] L. Cariddi,et al. Characterization of an Enterococcus faecium strain in a murine mastitis model , 2019, Journal of applied microbiology.
[5] Xiaoyu Li,et al. Evaluation of phage therapy in the treatment of Staphylococcus aureus-induced mastitis in mice , 2019, Folia Microbiologica.
[6] Guo-chun Ding,et al. Impact of direct application of biogas slurry and residue in fields: In situ analysis of antibiotic resistance genes from pig manure to fields. , 2018, Journal of hazardous materials.
[7] Jia Hua Cheng,et al. Cloning, Expression, and Immunogenicity of Fimbrial-F17A Subunit Vaccine against Escherichia coli Isolated from Bovine Mastitis , 2017, BioMed research international.
[8] Jian Sun,et al. Efficacy of Cefquinome against Escherichia coli Environmental Mastitis Assessed by Pharmacokinetic and Pharmacodynamic Integration in Lactating Mouse Model , 2017, Front. Microbiol..
[9] Jian Sun,et al. Dose Assessment of Cefquinome by Pharmacokinetic/Pharmacodynamic Modeling in Mouse Model of Staphylococcus aureus Mastitis , 2016, Front. Microbiol..
[10] Yahong Liu,et al. In Vivo Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Streptococcus suis Serotype 2 at Varied Initial Inoculum Sizes , 2015, Antimicrobial Agents and Chemotherapy.
[11] Alicia Rodríguez-Gascón,et al. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[12] M. Pimentel,et al. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. , 2014, International journal of antimicrobial agents.
[13] K. Breyne,et al. Short communication: Antimicrobial efficacy of intramammary treatment with a novel biphenomycin compound against Staphylococcus aureus, Streptococcus uberis, and Escherichia coli-induced mouse mastitis. , 2013, Journal of dairy science.
[14] C. Hudson,et al. Rate of transmission: a major determinant of the cost of clinical mastitis. , 2013, Journal of dairy science.
[15] Rahul Modak,et al. Histone H3K14 and H4K8 hyperacetylation is associated with Escherichia coli-induced mastitis in mice , 2012, Epigenetics.
[16] Laura J V Piddock,et al. The crisis of no new antibiotics--what is the way forward? , 2012, The Lancet. Infectious diseases.
[17] Suzanna Gim,et al. Rifaximin: new therapeutic indication and future directions. , 2011, Clinical therapeutics.
[18] Henk Hogeveen,et al. Economic aspects of mastitis: New developments , 2011, New Zealand veterinary journal.
[19] T. Vanden Berghe,et al. Inflammatory mediators in Escherichia coli-induced mastitis in mice. , 2008, Comparative immunology, microbiology and infectious diseases.
[20] A. Marchese,et al. Effects of Rifaximin on Bacterial Virulence Mechanisms at Supra- and Sub-Inhibitory Concentrations , 2008, Journal of chemotherapy.
[21] Steffen Jung,et al. Toll‐like receptor 4 is needed to restrict the invasion of Escherichia coli P4 into mammary gland epithelial cells in a murine model of acute mastitis , 2007, Cellular microbiology.
[22] M. J. Pons,et al. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. , 2007, Diagnostic microbiology and infectious disease.
[23] H. Dupont,et al. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] É. Brouillette,et al. The pathogenesis and control of Staphylococcus aureus-induced mastitis: study models in the mouse. , 2005, Microbes and infection.
[25] S. Levy,et al. Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.
[26] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[27] P. Maincent,et al. Bovine mastitis and intramammary drug delivery: review and perspectives. , 2001, Advanced drug delivery reviews.